Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05528952
Title Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma (TERTIO)
Acronym TERTIO
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Centre Hospitalier Universitaire de Besancon
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA

Facility Status City State Zip Country Details
CHU de Besançon RECRUITING Besançon France Details
Hôpital Henri Mondor RECRUITING Créteil France Details
Centre Georges François Leclerc RECRUITING Dijon France Details
Hôpital Nord Franche-Comté RECRUITING Montbéliard France Details
CHU de Montpellier RECRUITING Montpellier France Details
Centre Hospitalier Paris St Joseph NOT_YET_RECRUITING Paris France Details
Groupe Hospitalier Paris Salpetrière NOT_YET_RECRUITING Paris France Details
Hôpital BEAUJON RECRUITING Paris France Details
Institut Mutualiste Montsouris RECRUITING Paris France Details
Hôpital Paul Brousse RECRUITING Villejuif France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field